Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Nanobody System Tags, Grabs, Drags Proteins in the Cell

A nanobody-based system has been used to control intracellular protein localization and enable detailed investigation of wing development in the fruit fly. The system, its developers speculate, may help illuminate diverse mechanisms in developmental biology. I

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

A nanobody-based system has been used to control intracellular protein localization and enable detailed investigation of wing development in the fruit fly. The system, its developers speculate, may help illuminate diverse mechanisms in developmental biology. In this image, nanobodies in the wing precursor of a fruit fly larva are shown in pink. [University of Basel, Biozentrum]

An object’s function depends not only on its size, shape, and composition, but its location, too—as anyone who has ever been asked to arrange furniture knows. Moving a couch here or a table there can even alter the function of an entire room. Something similar can be said about proteins, and their positions within the cell. Yet the relocalization or even the deliberately mislocalization of proteins isn’t easily accomplished.

To accomplish the cellular equivalent of furniture arrangement, scientists based at the University of Basel have developed a nanobody-based system that can accomplish protein localization. The system, its creators assert, can be used with a wide range of proteins and in various areas of developmental biology.

The Basel team, led by developmental biologist Markus Affolter, Ph.D., used the nanobody system to investigate the growth of the wings of the fruit fly. Details of this work appeared April 11 in the journal eLife, in an article entitled “A Nanobody-Based Toolset to Investigate the Role of Protein Localization and Dispersal in Drosophila.”

According to the article’s authors, the nanobody system, called GrabFP (for grab Green Fluorescent Protein), is a collection of four nanobody-based green fluorescent protein (GFP) traps that localize to defined positions along the apical–basal axis. The localization preference of the GrabFP traps, they explained, can impose a novel localization on GFP-tagged target proteins and results in their controlled mislocalization.

“These new tools were used to mislocalize transmembrane and cytoplasmic GFP fusion proteins in the Drosophila wing disc epithelium and to investigate the effect of protein mislocalization,” they wrote. “Furthermore, we used the GrabFP system as a tool to study the extracellular dispersal of the Decapentaplegic (Dpp) protein and show that the Dpp gradient forming in the lateral plane of the Drosophila wing disc epithelium is essential for patterning of the wing imaginal disc.”

A repositioning of the proteins of interest requires labeling with GFP. Subsequently, so-called anti-GFP nanobodies, small antibody fragments derived from camels, are then used to bind and to move the GFP-tagged proteins to a new site in the living organism. The nanobody itself is linked to a signal protein that defines the destination of the target protein. Thus, the nanobody forces the GFP-tagged protein into a new position. “Even if we do not know exactly the composition and structure of a protein, we can label it with GFP and control the destination site by using nanobodies,” said Stefan Harmansa, Ph.D., one of the two first authors.

The researchers were able to transfer proteins to a new site, internal or external to the cell. “By transporting proteins to new locations, we can observe whether their function changes or not and whether development is affected,” says Ilaria Alborelli, Ph.D., also one of the first authors of the study.

So far, scientists have been restricted in relocating proteins. The new nanobody tool, however, makes it possible to easily and efficiently change the position of all GFP-tagged proteins and thus explore their functions. The Affolter group has already been successful in investigating the growth of Drosophila wings using this nanobody tool. By interfering with the signaling molecule Dpp in a position-dependent manner, the scientists have been able to show more precisely its influence on wing growth.

In the future, the new nanobody tool can be used for a wide variety of studies on organ growth and in various other areas of developmental biology, and the growth and the development of different cells and organs can be investigated in more detail.

The Affolter team also faces many new challenges, noted Harmansa: “We as developmental biologists are still confronted with urgent questions, such as how an organism knows when it has to stop its growth. To put it succinctly, how does it work that arms or legs stop growing when they reach their correct length?” In the future, this novel tool may contribute to a better understanding of how organ growth is regulated.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01How stable is the antibody?

A crucial question often addressed during preclinical development focuses on the in vivo stability of therapeutic antibodies. Increasing the half-life of a therapeutic antibody has several benefits ranging from higher treatment efficacy to increased advantages for the patients who will have a fewer number of therapy sessions and a reduced cost. Given these compelling benefits, following the identification of therapeutic antibodies with the desired specificity, developers usually subject them to a refinement step to increase their stability. This process is often hindered by the lack of reliable experimental tools to predict the half-life of antibodies in patients. The major hurdle of using mouse models to predict antibody stability in the serum lies in the way immunoglobulin proteins are processed by the organism. In mammals, most proteins circulating in the serum undergo constant uptake by endothelial cells and are routed through the endosomes to the lysosomal compartment for degradation. In the endosomes, immunoglobulin G (IgG) proteins are recognized and bound by a transmembrane protein, called the neonatal Fc receptor (FcRn), which mediates their recycling to the plasma membrane and subsequent release back into the serum. As a result, the half-life of IgGs are significantly extended by this mechanism. Since most therapeutic antibodies belong to the IgG class, this recycling system is very relevant for their relative stability in the body. Remarkably, the relative affinity between IgGs and FcRn is extremely disparate between different species, with the mouse receptor showing a much higher affinity than its human counterpart.

Source: www.genengnews.com ↗
02Undruggable or unscreenable?

Another obstacle to discovering new PPI inhibitors is the lack of libraries designed to hunt for them, points out Philippe Roche, PhD, senior scientist at the Integrative Structural and Chemical Biology team at the Cancer Research Center of Marseilles, France. “If you screen PPIs using libraries that were designed for kinases or GPCRs, that’s why you don’t get a lot of good results,” he says. To that end, his group began assembling a library focused on orthosteric inhibitors of PPIs. The result was 2P2Idb, a hand-curated, structural database cataloguing orthosteric inhibitors of PPIs for which the interface had been 3D characterized. From analyzing these known PPI inhibitors, and what structures they had in common, Roche and his colleagues developed a model to predict whether compounds would likely inhibit PPIs. Using this method, 2P2Idb creates an enriched screening library that dramatically increases the hit rate compared to standard libraries. Having proven their success with a small library of 1600 compounds, they are in the process of expanding the library to 10,000 compounds. Once that’s published, “the idea is to make this library available to labs around the world,” Roche says. “We will provide the library free of charge for people to be able to screen PPI targets.”

Source: www.genengnews.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →